JP2002541854A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002541854A5 JP2002541854A5 JP2000612481A JP2000612481A JP2002541854A5 JP 2002541854 A5 JP2002541854 A5 JP 2002541854A5 JP 2000612481 A JP2000612481 A JP 2000612481A JP 2000612481 A JP2000612481 A JP 2000612481A JP 2002541854 A5 JP2002541854 A5 JP 2002541854A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- recombinant protein
- virus
- proteins
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 102000007312 Recombinant Proteins Human genes 0.000 description 12
- 108010033725 Recombinant Proteins Proteins 0.000 description 12
- 241000700605 Viruses Species 0.000 description 4
- 239000002609 media Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 102000018358 Immunoglobulins Human genes 0.000 description 2
- 108060003951 Immunoglobulins Proteins 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 229920002676 Complementary DNA Polymers 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 108010046068 N-Acetyllactosamine Synthase Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 241000710778 Pestivirus Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 101710043164 Segment-4 Proteins 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 102000003838 Sialyltransferases Human genes 0.000 description 1
- 108090000141 Sialyltransferases Proteins 0.000 description 1
- 101700038759 VP1 Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 102000016350 Viral Proteins Human genes 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 101700005460 hemA Proteins 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Description
【特許請求の範囲】
【請求項1】 少なくとも一つの組み換え蛋白質を細胞内において生産するための方法であって、当該方法はECACC 寄託番号96022940として寄託されたPER.C6細胞又はその誘導体(derivative)である細胞を提供する過程を含み、前記方法は前記細胞に組み換え蛋白質をコードする遺伝子を与え、前記細胞を適切な培地中で培養する過程及び前記細胞及び/又は前記培地から組み換え蛋白質を回収する過程を含み、ここで前記組み換え蛋白質が、前記細胞のゲノム中に組み込まれた核酸によってコードされた蛋白質である、少なくとも一つの組み換え蛋白質を細胞内において生産するための方法。
【請求項2】 前記培養の間に前記細胞は懸濁液の状態である、請求項1記載の方法。
【請求項3】 前記適切な培地は動物またはヒト由来の血清を含まない培地である、請求項1又は請求項2記載の方法。
【請求項4】 前記組み換え蛋白質はヒト蛋白質である、請求項1−3のいずれか一つの請求項記載の方法。
【請求項5】 前記組み換え蛋白質がイムノグロブリンの少なくとも一つの可変領域を含む、請求項1−4のいずれか一つの請求項記載の方法。
【請求項6】 前記組み換え蛋白質がイムノグロブリンである、請求項5記載の方法。
【請求項7】 前記組み換え蛋白質がモノクローナル抗体である、請求項6記載の方法。
【請求項8】 前記組み換え蛋白質がエリスロポエチン、又は機能を有するその誘導体、相同物、又は断片である、請求項1−4のいずれか一つの請求項記載の方法。
【請求項9】 前記組み換え蛋白質がアデノウイルス蛋白質以外のウイルス蛋白質である、請求項1−4のいずれか一つの請求項記載の方法。
【請求項10】 前記ウイルス蛋白質が、インフルエンザウイルスニューラミダーゼ及び/又はヘマグルチニン;エンテロウイルス蛋白質;ヘルペスウイルス蛋白質;オルソミクソウイルス蛋白質;レトロウイルス、パルボウイルスまたはポパボウイルス蛋白質;ロータウイルス又はコロナウイルス蛋白質;風疹ウイルス蛋白質又はイースタン、ウエスタン、又はベネズエリアン(venezuelean)ウマ脳脊髄炎ウイルス蛋白質などのトガウイルス蛋白質;A型肝炎ウイルス蛋白質又はB型肝炎ウイルス蛋白質などの肝炎を引き起こすウイルスの蛋白質;ブタコレラウイルス蛋白質の様なペスティウイルス蛋白質、又は狂犬病ウイルス蛋白質の様なラブドウイルス蛋白質からなる群から選択された、請求項9記載の方法。
【請求項11】 前記組み換え蛋白質が、CMVプロモーターの制御下にある核酸によってコードされた蛋白質である、請求項1−10のいずれか一つの請求項記載の方法。
【請求項12】 前記細胞に、アルファ2,3−シアリルトランスフェラーゼ、アルファ2,6−シアリルトランスフェラーゼまたはベータ1,4−ガラクトシルトランスフェラーゼをコードするcDNAが更に組み込まれている、請求項1−11のいずれか一つの請求項記載の方法。
【請求項1】 少なくとも一つの組み換え蛋白質を細胞内において生産するための方法であって、当該方法はECACC 寄託番号96022940として寄託されたPER.C6細胞又はその誘導体(derivative)である細胞を提供する過程を含み、前記方法は前記細胞に組み換え蛋白質をコードする遺伝子を与え、前記細胞を適切な培地中で培養する過程及び前記細胞及び/又は前記培地から組み換え蛋白質を回収する過程を含み、ここで前記組み換え蛋白質が、前記細胞のゲノム中に組み込まれた核酸によってコードされた蛋白質である、少なくとも一つの組み換え蛋白質を細胞内において生産するための方法。
【請求項2】 前記培養の間に前記細胞は懸濁液の状態である、請求項1記載の方法。
【請求項3】 前記適切な培地は動物またはヒト由来の血清を含まない培地である、請求項1又は請求項2記載の方法。
【請求項4】 前記組み換え蛋白質はヒト蛋白質である、請求項1−3のいずれか一つの請求項記載の方法。
【請求項5】 前記組み換え蛋白質がイムノグロブリンの少なくとも一つの可変領域を含む、請求項1−4のいずれか一つの請求項記載の方法。
【請求項6】 前記組み換え蛋白質がイムノグロブリンである、請求項5記載の方法。
【請求項7】 前記組み換え蛋白質がモノクローナル抗体である、請求項6記載の方法。
【請求項8】 前記組み換え蛋白質がエリスロポエチン、又は機能を有するその誘導体、相同物、又は断片である、請求項1−4のいずれか一つの請求項記載の方法。
【請求項9】 前記組み換え蛋白質がアデノウイルス蛋白質以外のウイルス蛋白質である、請求項1−4のいずれか一つの請求項記載の方法。
【請求項10】 前記ウイルス蛋白質が、インフルエンザウイルスニューラミダーゼ及び/又はヘマグルチニン;エンテロウイルス蛋白質;ヘルペスウイルス蛋白質;オルソミクソウイルス蛋白質;レトロウイルス、パルボウイルスまたはポパボウイルス蛋白質;ロータウイルス又はコロナウイルス蛋白質;風疹ウイルス蛋白質又はイースタン、ウエスタン、又はベネズエリアン(venezuelean)ウマ脳脊髄炎ウイルス蛋白質などのトガウイルス蛋白質;A型肝炎ウイルス蛋白質又はB型肝炎ウイルス蛋白質などの肝炎を引き起こすウイルスの蛋白質;ブタコレラウイルス蛋白質の様なペスティウイルス蛋白質、又は狂犬病ウイルス蛋白質の様なラブドウイルス蛋白質からなる群から選択された、請求項9記載の方法。
【請求項11】 前記組み換え蛋白質が、CMVプロモーターの制御下にある核酸によってコードされた蛋白質である、請求項1−10のいずれか一つの請求項記載の方法。
【請求項12】 前記細胞に、アルファ2,3−シアリルトランスフェラーゼ、アルファ2,6−シアリルトランスフェラーゼまたはベータ1,4−ガラクトシルトランスフェラーゼをコードするcDNAが更に組み込まれている、請求項1−11のいずれか一つの請求項記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99201176 | 1999-04-15 | ||
EP99201176.7 | 1999-04-15 | ||
EP99204434 | 1999-12-21 | ||
EP99204434.7 | 1999-12-21 | ||
PCT/NL2000/000247 WO2000063403A2 (en) | 1999-04-15 | 2000-04-17 | Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2002541854A JP2002541854A (ja) | 2002-12-10 |
JP2002541854A5 true JP2002541854A5 (ja) | 2007-08-16 |
JP4210036B2 JP4210036B2 (ja) | 2009-01-14 |
Family
ID=26153302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000612481A Expired - Lifetime JP4210036B2 (ja) | 1999-04-15 | 2000-04-17 | ヒト細胞における組み換え蛋白質の生産 |
Country Status (18)
Country | Link |
---|---|
EP (3) | EP1533380B1 (ja) |
JP (1) | JP4210036B2 (ja) |
CN (1) | CN100457914C (ja) |
AT (3) | ATE536417T1 (ja) |
AU (1) | AU772352B2 (ja) |
CA (1) | CA2370477C (ja) |
CY (1) | CY1109759T1 (ja) |
DE (2) | DE60043273D1 (ja) |
DK (3) | DK1161548T4 (ja) |
ES (3) | ES2378272T3 (ja) |
HK (1) | HK1048138B (ja) |
IL (2) | IL145849A0 (ja) |
MX (1) | MXPA01010360A (ja) |
NO (1) | NO328951B1 (ja) |
NZ (1) | NZ514951A (ja) |
PT (2) | PT1161548E (ja) |
SI (2) | SI1533380T1 (ja) |
WO (1) | WO2000063403A2 (ja) |
Families Citing this family (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
WO2003050286A1 (en) * | 2001-10-29 | 2003-06-19 | Crucell Holland B.V. | Methods and means for producing proteins with predetermined post-translational modifications |
US7297680B2 (en) * | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
US7425437B2 (en) * | 1999-11-26 | 2008-09-16 | Crucell Holland B.V. | Vaccines against West Nile Virus |
US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
EP1256803A1 (en) | 2001-05-07 | 2002-11-13 | Crucell Holland B.V. | Methods for the identification of antiviral compounds |
BR0213402A (pt) * | 2001-10-29 | 2004-10-13 | Crucell Holland Bv | Métodos para identificar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para selecionar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para se obter uma célula de mamìfero a partir de uma população heterogênea de células, e para produzir uma molécula proteinácea, composição farmaceuticamente aceitável, eritropoietina recombinantemente produzida, usos de uma célula de mamìfero, da eritropoietina recombinantemente produzida, e de uma composição de moléculas semelhantes à eritropoietina, preparação farmacêutica, método para o tratamento preventivo e/ou terapêutico de um distúrbio, composição de moléculas semelhates à eritropoietina, métodos para produzir, em uma célula de mamìfero, moléculas proteináceas, para produzir uma fração enriquecida em uma molécula proteinácea, e para fracionar uma mistura que contém moléculas proteináceas, fração, e, usos de uma fração ou composição, e de eritropoietina recombinantemente produzìvel em uma célula de mamìfero |
AU2002225509A1 (en) * | 2001-12-07 | 2003-06-17 | Crucell Holland B.V. | Production and of viruses, viral isolates and vaccines |
NZ533124A (en) * | 2001-12-07 | 2005-11-25 | Crucell Holland B | Production of viruses, viral isolates and vaccines |
NZ533332A (en) * | 2001-12-17 | 2005-07-29 | Crucell Holland B | Efficient production of F(AB')2 fragments in mammalian cells |
KR100454016B1 (ko) * | 2002-01-05 | 2004-10-26 | 한국과학기술원 | 항예정사 유전자로 형질전환되고 dhfr 유전자가결핍된 신규한 cho 세포주, 그의 제조 방법 및 상기형질전환된 cho 숙주 세포를 이용한 목적단백질의 생산방법 |
CN1612747A (zh) * | 2002-01-09 | 2005-05-04 | 克鲁塞尔荷兰公司 | 促红细胞生成素在预防或治疗心力衰竭中的用途 |
US8287864B2 (en) | 2002-02-14 | 2012-10-16 | Immunomedics, Inc. | Structural variants of antibodies for improved therapeutic characteristics |
CN101914158A (zh) | 2002-02-14 | 2010-12-15 | 免疫医疗公司 | 抗cd 20抗体及其融合蛋白和使用方法 |
CA2478012C (en) | 2002-03-01 | 2012-06-19 | Immunomedics, Inc. | Internalizing anti-cd74 antibodies and methods of use |
AU2002307635A1 (en) * | 2002-04-19 | 2003-11-03 | Crucell Holland B.V. | Methods and means for producing proteins with predetermined post-translational modifications |
BR0311799A (pt) | 2002-06-14 | 2005-05-10 | Immunomedics Inc | Anticorpo monoclonal hpam4 |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
ES2368733T3 (es) | 2002-07-18 | 2011-11-21 | Merus B.V. | Producción recombinante de mezclas de anticuerpos. |
CA2494310A1 (en) | 2002-08-01 | 2004-02-12 | Immunomedics, Inc. | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
US7541440B2 (en) | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
US8524477B2 (en) | 2002-10-29 | 2013-09-03 | Crucell Holland B.V. | Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby |
US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
CN100383238C (zh) * | 2003-05-09 | 2008-04-23 | 克鲁塞尔荷兰公司 | E1-永生化的细胞培养物及培养所述细胞以提高从中获取的产物产量的方法 |
EP1626992B1 (en) * | 2003-05-23 | 2010-06-02 | Crucell Holland B.V. | Production of recombinant igm in per.c6 cells |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
CA2527694C (en) | 2003-05-30 | 2015-07-14 | Hendricus Renerus Jacobus Mattheus Hoogenboom | Fab library for the preparation of anti vegf and anti rabies virus fabs |
AU2004251890B2 (en) | 2003-06-25 | 2010-09-23 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
EP2216342B1 (en) | 2003-07-31 | 2015-04-22 | Immunomedics, Inc. | Anti-CD19 antibodies |
EP1508576A1 (en) * | 2003-08-20 | 2005-02-23 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
CN1863918B (zh) | 2003-10-02 | 2011-03-30 | 克鲁塞尔荷兰公司 | 用于重组腺病毒的包装细胞 |
WO2005059149A2 (en) * | 2003-12-12 | 2005-06-30 | Chromagenics B.V. | Improved protein production |
CA2554054C (en) | 2004-01-20 | 2013-06-04 | Merus B.V. | Mixtures of binding proteins |
DK1720972T3 (da) | 2004-03-05 | 2014-04-14 | Dsm Ip Assets Bv | Fremgangsmåde til celledyrkning ved hjælp af fortløbende perfusion og vekslende tangentialt flow |
NZ580607A (en) | 2004-05-27 | 2011-05-27 | Crucell Holland Bv | Binding molecules capable of neutralizing rabies virus and uses thereof |
WO2006040322A1 (en) | 2004-10-12 | 2006-04-20 | Crucell Holland B.V. | Binding molecules for treatment and detection of cancer |
AU2005300503B2 (en) | 2004-11-08 | 2010-12-16 | Chromagenics B.V. | Selection of host cells expressing protein at high levels |
AU2005303758B2 (en) | 2004-11-11 | 2011-04-28 | Crucell Holland B.V. | Compositions against SARS-coronavirus and uses thereof |
AU2005318171B2 (en) | 2004-12-20 | 2011-09-29 | Crucell Holland B.V. | Binding molecules capable of neutralizing West Nile virus and uses thereof |
US8475794B2 (en) | 2005-04-06 | 2013-07-02 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases |
US8349332B2 (en) | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
EP1879921B1 (en) | 2005-05-12 | 2011-04-27 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
EP1739179A1 (en) | 2005-06-30 | 2007-01-03 | Octapharma AG | Serum-free stable transfection and production of recombinant human proteins in human cell lines |
US8470318B2 (en) | 2005-11-07 | 2013-06-25 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
EP2455100A3 (en) * | 2005-11-07 | 2012-11-07 | The Rockefeller University | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
US20080206246A1 (en) * | 2006-04-05 | 2008-08-28 | Ravetch Jeffrey V | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
AR053416A1 (es) | 2005-11-10 | 2007-05-09 | Protech Pharma S A | Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac |
DE102005054628A1 (de) | 2005-11-16 | 2007-05-24 | Cevec Pharmaceuticals Gmbh | Verfahren zur Herstellung von permanenten humanen Zelllinien |
US7642078B2 (en) | 2005-12-28 | 2010-01-05 | Crucell Holland B.V. | Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby |
WO2007107578A1 (en) | 2006-03-20 | 2007-09-27 | Chromagenics B.V. | Expression augmenting dna fragments, use thereof, and methods for finding thereof |
EA022780B1 (ru) * | 2006-04-05 | 2016-03-31 | Дзе Рокфеллер Юниверсити | СПОСОБ ПОВЫШЕНИЯ ПРОТИВОВОСПАЛИТЕЛЬНОЙ АКТИВНОСТИ И СНИЖЕНИЯ ЦИТОТОКСИЧЕСКОЙ АКТИВНОСТИ ПРЕПАРАТА IgG |
HUE027099T2 (hu) | 2006-06-06 | 2016-08-29 | Crucell Holland Bv | Humán kötõmolekulák staphylococcus elleni ölõaktivitással és alkalmazásuk |
CA2654502C (en) | 2006-06-06 | 2015-07-14 | Crucell Holland B.V. | Human binding molecules having killing activity against enterococci and uses thereof |
BRPI0714347A2 (pt) | 2006-07-14 | 2013-05-07 | Dsm Ip Assets Bv | processo aperfeiÇoado para o cultivo de cÉlulas |
MY170607A (en) | 2006-09-07 | 2019-08-20 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
DK2450379T3 (da) | 2006-09-07 | 2016-02-08 | Crucell Holland Bv | Humane bindingsmolekyler, der er i stand til at neutralisere influenzavirus h5n1, og anvendelser deraf |
EP2091969A4 (en) * | 2006-10-27 | 2010-05-12 | Univ Rockefeller | POLYPEPTIDES WITH IMPROVED INFLAMMATORY INHIBITION AND REDUCED CYTOTOXIC PROPERTIES AND RELATED METHODS THEREFOR |
JP2010512306A (ja) * | 2006-10-27 | 2010-04-22 | ザ ロックフェラー ユニバーシティー | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
WO2009022656A1 (ja) | 2007-08-10 | 2009-02-19 | Toto Ltd. | 組換え哺乳動物細胞、組換え哺乳動物細胞の製造方法、および目的タンパク質の生産方法 |
ES2450998T3 (es) * | 2007-12-13 | 2014-03-26 | F. Hoffmann-La Roche Ag | Nuevas variantes de proteína de cubierta E1 de rubéola y su utilización en la detección de anticuerpos anti-rubéola |
WO2009126308A2 (en) * | 2008-04-11 | 2009-10-15 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for vaccine and virus production |
MX2010011598A (es) | 2008-04-22 | 2010-12-15 | Univ Rockefeller | Metodos para identificar compuestos anti-inflamatorios. |
CA2728477C (en) * | 2008-07-15 | 2017-02-28 | Crucell Holland B.V. | Scalable process for culturing per.c6 cells and producing products therefrom |
EP2318048B1 (en) | 2008-07-21 | 2019-05-29 | Immunomedics, Inc. | Structural variants of antibodies for improved therapeutic characteristics |
AU2010244592B2 (en) | 2009-04-23 | 2016-05-19 | Janssen Vaccines & Prevention B.V. | Recombinant human alpha1-antitrypsin |
MY183517A (en) | 2009-05-11 | 2021-02-24 | Janssen Vaccines & Prevention Bv | Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof |
EP2484761A4 (en) | 2009-10-01 | 2013-11-27 | Toto Ltd | DNA CONSTRUCT AND METHOD FOR PRODUCING RECOMBINANT CHO CELLS THEREWITH |
HUE026229T2 (en) | 2010-02-08 | 2016-06-28 | Regeneron Pharma | Common light chain mouse |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
CN103906763B (zh) | 2011-07-14 | 2016-10-12 | 克鲁塞尔荷兰公司 | 能够中和系统发育群1和系统发育群2的a型流感病毒以及b型流感病毒的人结合分子 |
EP2739740B1 (en) | 2011-08-05 | 2019-10-02 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
WO2013093760A2 (en) | 2011-12-19 | 2013-06-27 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
CN102827273A (zh) * | 2012-02-16 | 2012-12-19 | 张小莺 | 抗痘苗病毒IgY抗体的制备 |
DK2822968T3 (en) | 2012-03-08 | 2018-04-16 | Janssen Vaccines & Prevention Bv | HUMAN BINDING MOLECULES ABLE TO BIND AND NEUTRALIZE INFLUENZA-B-VIRA, AND APPLICATIONS THEREOF |
KR102382304B1 (ko) | 2012-04-20 | 2022-04-04 | 메뤼스 엔.페. | Ig-유사 분자의 제조방법 및 제조수단 |
US9657290B2 (en) * | 2012-07-03 | 2017-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Scalable bio-element analysis |
CN104736174B (zh) | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
CN104662041A (zh) | 2012-09-27 | 2015-05-27 | 克鲁塞尔荷兰公司 | 能够结合到并且中和b型肝炎病毒的人类结合分子及其用途 |
CN105051066B (zh) | 2012-09-27 | 2019-08-06 | 美勒斯公司 | 作为T细胞衔接器的双特异性IgG抗体 |
CA2908878C (en) | 2013-04-15 | 2021-06-29 | Crucell Holland B.V. | Human antibodies binding to rsv g protein |
CA2908921C (en) | 2013-04-15 | 2022-07-19 | Crucell Holland B.V. | Human antibodies binding to rsv g protein |
DE112014003136A5 (de) | 2013-07-01 | 2016-04-21 | Charité - Universitätsmedizin Berlin | Immortalisierte humane Chorionzelllinie sowie Verfahren zur Immortalisierung humaner Chorionzellen |
CN104693308B (zh) * | 2013-12-05 | 2020-08-04 | 同济大学 | 感受胞内pH变化的Smad5蛋白及其应用 |
EP2883883A1 (en) | 2013-12-16 | 2015-06-17 | Cardio3 Biosciences S.A. | Therapeutic targets and agents useful in treating ischemia reperfusion injury |
SI3110849T1 (sl) | 2014-02-28 | 2021-01-29 | Merus N.V. | Protitelo, ki veže ERBB-2 in ERBB-3 |
AU2015223566B2 (en) | 2014-02-28 | 2020-10-08 | Merus N.V. | Antibodies that bind EGFR and ErbB3 |
EP3119194B1 (en) | 2014-03-21 | 2021-04-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
TWI743024B (zh) | 2014-06-06 | 2021-10-21 | 美商健臻公司 | 灌注培養方法及其用途 |
US10174127B2 (en) | 2015-02-05 | 2019-01-08 | Janssen Vaccines & Prevention B.V. | Human neutralizing antibodies binding to influenza neuraminidase |
MX2017010009A (es) | 2015-02-05 | 2017-10-24 | Janssen Vaccines & Prevention Bv | Moléculas de unión dirigidas contra hemaglutinina de virus influenza y usos de las mismas. |
EP3259385A4 (en) | 2015-02-22 | 2018-07-25 | The Board of Trustees of the Leland Stanford Junior University | Micro-screening apparatus, process, and products |
AU2016232715A1 (en) | 2015-03-19 | 2017-09-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
LT3115376T (lt) | 2015-07-10 | 2018-11-12 | Merus N.V. | Antikūnai, kurie jungiasi su žmogaus cd3 |
SI3365373T1 (sl) | 2015-10-23 | 2021-08-31 | Merus N.V. | Vezne molekule, ki zaviranjo rast raka |
US10703803B2 (en) | 2016-03-01 | 2020-07-07 | Janssen Vaccines & Prevention B.V. | Human neutralizing antibodies binding to influenza B neuraminidase |
CN110198786A (zh) | 2016-11-14 | 2019-09-03 | 浩康生物系统公司 | 用于分选目标颗粒的方法和装置 |
JP7109467B2 (ja) | 2017-03-28 | 2022-07-29 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | タウに特異的に結合する結合分子 |
WO2018182422A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
US20200033347A1 (en) | 2017-04-18 | 2020-01-30 | Universite Libre De Bruxelles | Biomarkers And Targets For Proliferative Diseases |
SG11202001050PA (en) | 2017-08-09 | 2020-03-30 | Merus Nv | Antibodies that bind egfr and cmet |
EP3693013A4 (en) | 2017-10-06 | 2021-06-30 | Ono Pharmaceutical Co., Ltd. | BISPECIFIC ANTIBODY |
AU2018380765A1 (en) | 2017-12-04 | 2020-06-11 | Janssen Vaccines & Prevention B.V. | Binding molecules that specifically bind to tau |
CA3089923A1 (en) | 2018-02-01 | 2019-08-08 | Janssen Vaccines & Prevention B.V. | Binding molecules that specifically bind to tau |
TWI804572B (zh) | 2018-02-09 | 2023-06-11 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
CA3088676A1 (en) | 2018-03-23 | 2019-09-26 | Universite Libre De Bruxelles | Wnt signaling agonist molecules |
TW202102544A (zh) | 2019-04-04 | 2021-01-16 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
TWI809286B (zh) | 2019-07-05 | 2023-07-21 | 日商小野藥品工業股份有限公司 | 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療 |
JP6856183B1 (ja) | 2019-07-30 | 2021-04-07 | 小野薬品工業株式会社 | 二重特異性抗体 |
JPWO2021025140A1 (ja) | 2019-08-08 | 2021-02-11 | ||
AU2022288080A1 (en) * | 2021-06-11 | 2023-12-07 | Monsanto Technology Llc | Methods and compositions for altering protein accumulation |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2573436B1 (fr) * | 1984-11-20 | 1989-02-17 | Pasteur Institut | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins |
US4892737A (en) * | 1988-09-22 | 1990-01-09 | University Of Florida | Composition and method for enhancing permeability of topical drugs |
GB8900483D0 (en) * | 1989-01-10 | 1989-03-08 | Celltech Ltd | Recombinant dna method |
EP0596881B1 (fr) * | 1991-08-01 | 1997-03-19 | Fondation Nationale De Transfusion Sanguine | Expression dans des lignees lymphoblastoides humaines non-tumorales avec un vecteur integratif |
DK0667912T3 (da) * | 1993-07-13 | 2008-11-10 | Centelion | Defekte adenovirusvektorer og anvendelse heraf i genterapi |
US5610043A (en) * | 1994-04-28 | 1997-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Human prostatic cell lines immortalized by adenovirus 12-simian virus 40 (AD12/SV40) hybrid virus |
JP4051416B2 (ja) * | 1995-06-15 | 2008-02-27 | クルーセル ホランド ベスローテン フェンノートシャップ | 遺伝子治療に使用されるヒト組換えアデノウイルス用のパッケージングシステム |
-
2000
- 2000-04-17 AT AT09174441T patent/ATE536417T1/de active
- 2000-04-17 CN CNB008089388A patent/CN100457914C/zh not_active Expired - Lifetime
- 2000-04-17 AU AU41520/00A patent/AU772352B2/en not_active Expired
- 2000-04-17 EP EP05100732A patent/EP1533380B1/en not_active Expired - Lifetime
- 2000-04-17 ES ES09174441T patent/ES2378272T3/es not_active Expired - Lifetime
- 2000-04-17 NZ NZ514951A patent/NZ514951A/xx not_active IP Right Cessation
- 2000-04-17 IL IL14584900A patent/IL145849A0/xx unknown
- 2000-04-17 DK DK00921175.6T patent/DK1161548T4/da active
- 2000-04-17 CA CA2370477A patent/CA2370477C/en not_active Expired - Lifetime
- 2000-04-17 MX MXPA01010360A patent/MXPA01010360A/es active IP Right Grant
- 2000-04-17 EP EP00921175A patent/EP1161548B2/en not_active Expired - Lifetime
- 2000-04-17 DK DK09174441.7T patent/DK2163640T3/da active
- 2000-04-17 AT AT05100732T patent/ATE447617T1/de active
- 2000-04-17 PT PT00921175T patent/PT1161548E/pt unknown
- 2000-04-17 SI SI200031051T patent/SI1533380T1/sl unknown
- 2000-04-17 ES ES00921175T patent/ES2237420T5/es not_active Expired - Lifetime
- 2000-04-17 DE DE60043273T patent/DE60043273D1/de not_active Expired - Lifetime
- 2000-04-17 WO PCT/NL2000/000247 patent/WO2000063403A2/en active IP Right Grant
- 2000-04-17 PT PT05100732T patent/PT1533380E/pt unknown
- 2000-04-17 ES ES05100732T patent/ES2335775T3/es not_active Expired - Lifetime
- 2000-04-17 SI SI200030662T patent/SI1161548T2/sl unknown
- 2000-04-17 EP EP09174441A patent/EP2163640B1/en not_active Expired - Lifetime
- 2000-04-17 DE DE60018171T patent/DE60018171T3/de not_active Expired - Lifetime
- 2000-04-17 JP JP2000612481A patent/JP4210036B2/ja not_active Expired - Lifetime
- 2000-04-17 AT AT00921175T patent/ATE289354T1/de active
- 2000-04-17 DK DK05100732.6T patent/DK1533380T3/da active
-
2001
- 2001-10-10 IL IL145849A patent/IL145849A/en not_active IP Right Cessation
- 2001-10-12 NO NO20014977A patent/NO328951B1/no not_active IP Right Cessation
-
2003
- 2003-01-14 HK HK03100323.5A patent/HK1048138B/zh unknown
-
2010
- 2010-01-27 CY CY20101100084T patent/CY1109759T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002541854A5 (ja) | ||
JP2004501647A5 (ja) | ||
US5543328A (en) | Adenoviruses having modified fiber proteins | |
Smerdou et al. | Two-helper RNA system for production of recombinant Semliki forest virus particles | |
Casais et al. | Reverse genetics system for the avian coronavirus infectious bronchitis virus | |
Strauss et al. | Replication strategies of the single stranded RNA viruses of eukaryotes | |
EP0073656B1 (en) | Preparation of polypeptides in vertebrate cell culture | |
JP2004500842A5 (ja) | ||
DK0702085T3 (da) | Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus | |
JP2009501001A5 (ja) | ||
DE69638196D1 (de) | Rekombinantes sendai-virus | |
WO2001039797A3 (en) | Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus | |
Inoue et al. | A new Sendai virus vector deficient in the matrix gene does not form virus particles and shows extensive cell-to-cell spreading | |
CA2272046A1 (en) | Infectious clones of rna viruses and vaccines and diagnostic assays derived thereof | |
IL145702A (en) | Method of preparing infectious influenza viruses in the absence of a helper virus | |
JP2003530064A (ja) | 遺伝子治療用のコートタンパク質改変バキュロウイルス−ベクター | |
CN111218477B (zh) | 靶向感染哺乳动物细胞的禽4型腺病毒载体及其应用 | |
JP2004501646A5 (ja) | ||
Liao et al. | Coronavirus defective-interfering RNA as an expression vector: the generation of a pseudorecombinant mouse hepatitis virus expressing hemagglutinin-esterase | |
JP2011523642A5 (ja) | ||
Chatterjee et al. | Effect of monensin on Mason-Pfizer monkey virus glycoprotein synthesis | |
CA2289776A1 (en) | An infectious clone for human parainfluenza virus type 3 | |
JPH0692996A (ja) | C型肝炎ウィルス粒子を構成する蛋白質およびその発現 | |
DE60335139D1 (de) | Virusähnliche partikel, verfahren zur herstellung und immunogene zusammensetzungen | |
Fenner et al. | Viral replication |